Advancements and New Treatment Options: Optimizing Care for Patients with Graft-vs-Host Disease : Episode 7
Approved Therapies for Steroid-Refractory Chronic GvHD
Hematologist-oncologists give an overview of the 3 approved treatment options for patients with steroid-refractory chronic GvHD—ruxolitinib, ibrutinib, and belumosudil—and highlight the REACH3 and ROCKstar studies.
EP: 1.Overview of Graft-vs-Host Disease (GvHD)
EP: 2.How Does GvHD Typically Present?
EP: 3.Role of Biomarkers in Graft-vs-Host Disease
EP: 4.Staging Practices for Chronic Graft-vs-Host Disease
EP: 5.First-Line Therapy for Chronic GvHD
EP: 6.Treating Patients With Steroid-Refractory Chronic GvHD
Now Viewing
EP: 7.Approved Therapies for Steroid-Refractory Chronic GvHD
EP: 8.Therapies in Development for Chronic GvHD
EP: 9.Supportive Care and Medication Access in GvHD
Related Videos
Related Content
